High-density lipoproteins (HDL) are a negative (protective) risk factor for cardiovascular disease. There has been great interest in how the remodeling of HDL by plasma factors might contribute to cardioprotection. A phospholipid transfer protein (PLTP) in human plasma is a key protein in the remodeling of HDL. Although recent studies have shown that PLTP modifies HDL structure and composition even in the absence of other plasma factors, the mechanism by which this occurs remains to be elucidated. We propose three aims that will test eight hypotheses concerning the remodeling mechanism. They are as follows:
Aim 1 : To identify the mechanism(s) by which PLTP remodels HDL, according to the following hypotheses: a] The remodeling of HDL is specific for apolipoprotein (apo) A-I. b] PLTP-independent HDL fusion occurs through a hydrophobic patch on the HDL surface. c] HDL3 fusion, which follows PLTP-mediated apo A-I release and patch formation, is independent of PLTP. d] Fusion but not lipid transfer is inhibited by a net positive or negative charge on HDL. e] The small HDL formed by PLTP are preferential acceptors for cholesterol and a preferred substrate for LCAT. f] Phospholipid transfer is an obligatory precursor of cholesteryl ester transfer.
Aim 2 : To identify the determinants of PLTP molecular transfer specificity.
This aim will address the hypothesis that the molecular specificity of PLTP is determined by its affinity for and binding to monomeric lipid.
Aim 3 : To identify the effects of PLTP on the interaction of plasma lipoproteins with macrophage-derived lipoproteins.
This aim will address the hypothesis that PLTP is a key mediator of the association of macrophage-derived lipoproteins with more mature forms of HDL. The major techniques to be employed are site-directed mutagenesis, assays of lecithin:cholesterol acyltransferase and phospholipase activity, tissue culture (P388D1 macrophages), equilibrium measurements and lipid and protein assays.
| Gillard, Baiba K; Rosales, Corina; Xu, Bingqing et al. (2018) Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. J Clin Lipidol 12:849-856 |
| Xu, Bingqing; Gillard, Baiba K; Gotto Jr, Antonio M et al. (2017) ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate. Arterioscler Thromb Vasc Biol 37:2260-2270 |
| Jarrett, Kelsey E; Lee, Ciaran M; Yeh, Yi-Hsien et al. (2017) Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep 7:44624 |
| Gillard, Baiba K; Bassett, G Randall; Gotto Jr, Antonio M et al. (2017) Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. J Biol Chem 292:8864-8873 |
| Yelamanchili, Dedipya; Gillard, Baiba K; Gotto Jr, Antonio M et al. (2017) Structural Stability of Streptococcal Serum Opacity Factor. Protein J 36:196-201 |
| Pownall, Henry J; Gotto Jr, Antonio M (2016) New Insights into the High-Density Lipoprotein Dilemma. Trends Endocrinol Metab 27:44-53 |
| Murray, Stephen C; Gillard, Baiba K; Ludtke, Steven J et al. (2016) Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. Biophys J 110:810-6 |
| Pownall, Henry J; Schwartz, Anne V; Bray, George A et al. (2016) Changes in regional body composition over 8 years in a randomized lifestyle trial: The look AHEAD study. Obesity (Silver Spring) 24:1899-905 |
| Yang, Yaliu; Rosales, Corina; Gillard, Baiba K et al. (2016) Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo. Biochim Biophys Acta 1861:1787-1795 |
| Rosales, C; Davidson, W S; Gillard, B K et al. (2016) Speciated High-Density Lipoprotein Biogenesis and Functionality. Curr Atheroscler Rep 18:25 |
Showing the most recent 10 out of 68 publications
